PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35103348-10 2022 The novel CYP3A5*3*6*7 metabolic composite was the significant covariate accounting for 15%-19% of tacrolimus variability in dose (p = 0.002); AUC0-12 h * (p < 0.001), and Cl (p < 0.001). Tacrolimus 99-109 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 10-16 35103348-11 2022 CONCLUSIONS: Tacrolimus pharmacokinetics and adverse effects were different among stable kidney transplant recipient groups based upon race and sex with interpatient variability associated with the CYP3A5*3*6*7 metabolic composite. Tacrolimus 13-23 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 198-204